Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FLL029
MIFTS: 29

Fallopian Tube Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Fallopian Tube Disease

About this section

MalaCards integrated aliases for Fallopian Tube Disease:

Name: Fallopian Tube Disease 12 15
Fallopian Tube Diseases 44 73

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1962
MeSH 44 D005184
NCIt 50 C26771
UMLS 73 C0015556
Sources

Summaries for Fallopian Tube Disease

About this section
Disease Ontology : 12 A female reproductive system disease that is located in the fallopian tube.

MalaCards based summary : Fallopian Tube Disease, also known as fallopian tube diseases, is related to salpingitis and extrapelvic endometriosis. An important gene associated with Fallopian Tube Disease is MT-TG (Mitochondrially Encoded TRNA Glycine). The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include the fallopian tube, ovary and uterus, and related phenotype is Synthetic lethal with cisplatin.

Wikipedia : 76 The fallopian tubes, also known as uterine tubes or salpinges (singular salpinx) are uterine appendages,... more...

Sources

Related Diseases for Fallopian Tube Disease

About this section

Diseases related to Fallopian Tube Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 salpingitis 31.8 OVGP1 POC1A
2 extrapelvic endometriosis 10.4
3 hereditary site-specific ovarian cancer syndrome 10.2 BRCA1 BRCA2
4 breast reconstruction 10.2 BRCA1 BRCA2
5 tuberculous salpingitis 10.2 BRCA1 BRCA2
6 nosophobia 10.2 BRCA1 BRCA2
7 cancerophobia 10.2 BRCA1 BRCA2
8 breast-ovarian cancer, familial 1 10.2 BRCA1 BRCA2
9 synchronous bilateral breast carcinoma 10.2 BRCA1 BRCA2
10 glycogen-rich clear cell breast carcinoma 10.2 BRCA1 BRCA2
11 premature menopause 10.2 BRCA1 BRCA2
12 urethritis 10.2 EXTL3 MT-TG
13 peritoneum cancer 10.2 BRCA1 BRCA2
14 bilateral breast cancer 10.2 BRCA1 BRCA2
15 primary peritoneal carcinoma 10.2 BRCA1 BRCA2
16 lynch syndrome i 10.2 BRCA1 BRCA2
17 mutagen sensitivity 10.2 BRCA1 BRCA2
18 fanconi anemia, complementation group q 10.2 BRCA1 BRCA2
19 pre-malignant neoplasm 10.2 BRCA1 BRCA2
20 fallopian tube carcinoma 10.2 BRCA1 BRCA2
21 breast carcinoma in situ 10.1 BRCA1 BRCA2
22 ovarian cancer 1 10.1 BRCA1 BRCA2
23 malignant ovarian surface epithelial-stromal neoplasm 10.1 BRCA1 BRCA2
24 anus disease 10.1 EXTL3 MT-TG MTRR
25 rectal disease 10.1 EXTL3 MT-TG MTRR
26 ovary epithelial cancer 10.1 BRCA1 BRCA2
27 female breast cancer 10.0 BRCA1 BRCA2
28 trichomoniasis 10.0 ATAD2 EXTL3 WASF3
29 vaginal discharge 10.0 EXTL3 MAPK8IP1
30 fallopian tube adenocarcinoma 9.9 BRCA1 BRCA2 MAPK8IP1
31 dysgerminoma of ovary 9.9 BRCA1 BRCA2 MAPK8IP1
32 female reproductive system disease 9.9 BRCA1 BRCA2 MAPK8IP1
33 reproductive system disease 9.9 BRCA1 BRCA2 MAPK8IP1
34 isolated growth hormone deficiency, type ia 9.9 BRCA2 POC1A
35 urethral syndrome 9.8 EXTL3 IER3IP1 MT-TG MTRR WASF3

Graphical network of the top 20 diseases related to Fallopian Tube Disease:



Diseases related to Fallopian Tube Disease
Sources

Symptoms & Phenotypes for Fallopian Tube Disease

About this section

GenomeRNAi Phenotypes related to Fallopian Tube Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2
Sources

Drugs & Therapeutics for Fallopian Tube Disease

About this section

Drugs for Fallopian Tube Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Mechlorethamine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 51-75-2 4033
4
Ifosfamide Approved Phase 2, Phase 3,Phase 3 3778-73-2 3690
5
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
10
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
12
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
13
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
16
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
19
leucovorin Approved Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
20
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
21
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
22
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
23
Rucaparib Approved, Investigational Phase 3,Phase 1,Phase 2 283173-50-2 9931954
24
Nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
25
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
26
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037
28
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 56-86-0 33032
29
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
30
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
31
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
32
Cediranib Investigational Phase 2, Phase 3,Phase 3,Phase 1 288383-20-0 9933475
33
Maleic acid Experimental Phase 2, Phase 3,Phase 3,Phase 1 110-16-7 444266
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
37
Isophosphamide mustard Phase 2, Phase 3,Phase 3 0
38 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
39 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
40 Estrogens Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
44 Estrogen Receptor Antagonists Phase 3,Phase 2
45 Selective Estrogen Receptor Modulators Phase 3,Phase 2
46 Estrogen Antagonists Phase 3,Phase 2
47 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
49 taxane Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 549)
# Name Status NCT ID Phase Drugs
1 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
2 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
3 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
4 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
5 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
6 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
7 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
8 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
9 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
10 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
12 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
13 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
14 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
15 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
16 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
17 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
18 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
19 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
20 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
21 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
22 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
23 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
24 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
25 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
26 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
27 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
28 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
29 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
30 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
31 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
32 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
33 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
34 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
35 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
36 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Recruiting NCT03522246 Phase 3 Rucaparib;Nivolumab;Placebo Oral Tablet;Placebo IV Infusion
37 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
38 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
39 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
40 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
41 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
42 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
43 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
44 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
45 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01849874 Phase 3 MEK162, MEK inhibitor; oral;Physician's choice chemotherapy
46 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting NCT02631876 Phase 3 IMGN853;Paclitaxel;Doxorubicin;Topotecan
47 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
48 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting NCT01968213 Phase 3 Rucaparib;Placebo
49 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Active, not recruiting NCT01506856 Phase 2, Phase 3 Paclitaxel(intravenous) + Carboplatin(intravenous);Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
50 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin

Search NIH Clinical Center for Fallopian Tube Disease

Cochrane evidence based reviews: fallopian tube diseases

Sources

Genetic Tests for Fallopian Tube Disease

About this section
Sources

Anatomical Context for Fallopian Tube Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Disease:

19
The Fallopian Tube

MalaCards organs/tissues related to Fallopian Tube Disease:

41
Ovary, Uterus, Breast
Sources

Publications for Fallopian Tube Disease

About this section

Articles related to Fallopian Tube Disease:

# Title Authors Year
1
Fallopian tube disease in the nonpregnant patient. ( 21415195 )
2011
2
Fallopian tube disease: the cobblestone pattern as a radiographic sign. ( 11058655 )
2000
3
Fallopian tube disease: limited value of treatment with fallopian tube catheterization. ( 8259393 )
1994
4
Obstetrics, Gynæcology, and Pædiatrics: Post-Mortem Delivery-Stypticin in Uterine Hæmorrhage-The Ultimate Fate of Placental Tissue Retained in Utero-Congenital Luxation of Knee-Extra Uterine Gestation-Antiseptic Performance of Embryotomy-Conservation of the Ovary in Hysterectomy and Hystero-Myomectomy-Conservative Surgery of Uterine Appendages-Conservative Treatment of Fallopian-Tube Disease. ( 29001737 )
1898
Sources

Variations for Fallopian Tube Disease

About this section
Sources

Expression for Fallopian Tube Disease

About this section
Search GEO for disease gene expression data for Fallopian Tube Disease.
Sources

Pathways for Fallopian Tube Disease

About this section
Sources

GO Terms for Fallopian Tube Disease

About this section

Cellular components related to Fallopian Tube Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Fallopian Tube Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.16 BRCA1 BRCA2
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 BRCA1 BRCA2
3 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2
Sources

Sources for Fallopian Tube Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....